Literature DB >> 6778194

Encainide: a new and potent antiarrhythmic agent.

D C Harrison, R Winkle, M Sami, J Mason.   

Abstract

Encainide is a potent Class I antiarrhythmic drug that prolongs conduction in the His-Purkinje system. It produces only minimal hemodynamic changes in the normal or depressed left ventricle. Studies to date demonstrate excellent effectiveness against ventricular arrhythmia, and in comparative studies with quinidine, encainide was superior in reducing the frequency and complexity of ventricular premature beats in patients late after myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6778194     DOI: 10.1016/0002-8703(80)90212-4

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

Review 1.  Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST.

Authors:  T J Campbell
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

Review 2.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

3.  Depression of maximum rate of depolarization of guinea-pig ventricular action potentials by metabolites of encainide.

Authors:  P D Hemsworth; T J Campbell
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

4.  Pharmacokinetics of encainide in patients with cirrhosis.

Authors:  G Wensing; H Mönig; E E Ohnhaus; H P Hoensch
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

5.  Approaching the in vitro clinical trial: engineering organs on chips.

Authors:  A K Capulli; K Tian; N Mehandru; A Bukhta; S F Choudhury; M Suchyta; K K Parker
Journal:  Lab Chip       Date:  2014-09-07       Impact factor: 6.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.